Compare Adaptive Biotechnologies Corp (ADPT) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Tyson Foods, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.11 (market cap $4.04B), while Tyson Foods, Inc. trades at $55.7 (market cap $19.85B). The key difference: Tyson Foods, Inc. is far larger — about 4.9× Adaptive Biotechnologies Corp's market cap, and Tyson Foods, Inc. pays a 3.62% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TSN | |
|---|---|---|
Market Cap | $4.04B | $19.85B |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $68.75 |
52-Week Low | $12.30 | $50.72 |
Enterprise Value | $4.10B | $27.12B |
Dividend Yield | — | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Tyson Foods (TSN) trades at $57.16, down 1.52% on the day, amid a bearish technical signal. The company reported mixed Q3 2026 earnings, beating EPS estimates but missing revenue expectations, with beef segment losses weighing on results. Analyst consensus is a Buy with a $68.50 price target, but technical indicators show selling pressure. Recent news highlights debt tender offers and a maintained dividend, while cash flow trends show volatility.
The outlook is cautious; strong chicken and prepared foods segments provide stability, but persistent beef losses and volume declines pose near-term risks. Valuation metrics like P/E of 34.83 appear elevated relative to modest profitability, yet the stock trades below analyst targets, suggesting potential upside if operational challenges ease.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
